THC
Tetrahydrocannabinol is the main intoxicating cannabinoid. Its effects on attention, perception and mood can include unwanted anxiety or paranoia. A higher THC percentage is not a measure of medical quality. Source
← Treatments & evidence
TREATMENTS · CANNABIS & CANNABINOIDS
Understand the possibilities. Know the limits.
THC, CBD, terpenes, indica and sativa can be confusing. Start with the specific symptom, the actual formulation and the quality of the research—not a strain name or a promise.
Sources checked October 8, 2026 · Educational editorial draft; clinical review pending.
Psychosis and schizophrenia deserve particular caution. Cannabis can cause anxiety, paranoia and disorientation, and its use is associated with psychosis and schizophrenia. It should not be presented as a self-treatment for these conditions. If there is a history of psychosis, discuss any cannabis or CBD question with the treating psychiatrist before use. Source
This guide does not recommend a product, strain or dose. It separates medicines approved for particular indications from early research and consumer claims. Do not stop or change prescribed treatment because of something you read here.
WHAT “USED AS MEDICINE” MEANS
One plant. Different compounds. Very different evidence.
CBD
Cannabidiol is not intoxicating in the same way as THC, but it is pharmacologically active. It can affect other medicines and cause adverse effects; “CBD” does not mean harmless or equivalent to a prescription formulation. Source
| Specific use | What is established | What this does not establish |
|---|---|---|
| Certain seizure disorders | Prescription purified CBD, Epidiolex, is FDA-approved for seizures associated with Lennox–Gastaut syndrome, Dravet syndrome or tuberous sclerosis complex in patients aged one year and older. Source | Approval does not extend to treating autism, anxiety or OCD, or to retail CBD oils. |
| Selected cancer-treatment and HIV/AIDS symptoms | Dronabinol and nabilone have particular approved medical uses, including chemotherapy-related nausea; dronabinol also has an indication for AIDS-related appetite and weight loss. Source | These defined indications do not establish benefit for all symptoms or all cannabis products. |
| Chronic pain and multiple-sclerosis symptoms | Some cannabinoid preparations show modest symptom benefits, with important adverse effects and variation between studies. Source | Evidence for pain cannot be transferred to psychiatric conditions, or to any product sold under a similar name. |
The FDA has not approved the cannabis plant itself to treat a disease. State-authorized medical cannabis access and FDA drug approval are different systems. Source
EVIDENCE BY QUESTION
Could it help anxiety, OCD or autism-related difficulties?
Anxiety
Small studies suggest possible benefits of CBD in some anxiety settings, including public-speaking tasks. That does not establish a reliable long-term treatment for an anxiety disorder. THC can also provoke anxiety and paranoia. Source · Source
Discuss the actual anxiety problem and compare with established care, including CBT for anxiety.
OCD
A small placebo-controlled laboratory study with 12 completers found no advantage of smoked THC- or CBD-dominant cannabis over placebo for acute OCD symptoms. Anxiety improved less with cannabis than with placebo. This does not resolve every future cannabinoid question, but it does not support calling cannabis an established OCD treatment. Source
Keep ERP and condition-specific care central to the discussion.
Autism-related symptoms
A 2026 pilot crossover trial in 29 autistic children did not find a significant benefit on its primary social-responsiveness measure. Some secondary anxiety, social-relating and parental-stress measures improved; adaptive functioning did not. A small trial with mixed endpoints is a reason for further study, not proof of routine benefit. Source
The goal is support for distressing co-occurring symptoms and quality of life, not changing a person’s identity. Results in children cannot simply be assumed to apply to adults.
Psychosis or schizophrenia
THC-containing cannabis carries important psychiatric risks. Research on a purified compound is not evidence that retail cannabis treats psychosis or is safe for someone with schizophrenia. Bring the complete medication list and psychiatric history to the treating team. Source
Specialized psychosis care →BEYOND THE STRAIN NAME
Indica, sativa, hybrids & terpenes
Indica and sativa are not dependable treatment categories. Research comparing labeled samples found that these names poorly captured overall genetic and chemical differences. Even samples with the same cultivar name could differ substantially. “Indica for anxiety” and “sativa for energy” are not reliable medical rules. Source
Terpenes contribute to a plant’s aroma and taste. Researchers are studying how they act alone and with cannabinoids. The “entourage effect” is the proposed idea that components change one another’s effects; a plausible mechanism does not establish a clinically effective combination. Source
| Terpene | Useful context | Evidence boundary |
|---|---|---|
| Limonene | A 2024 controlled laboratory study in 20 healthy adults found that adding d-limonene reduced some THC-induced anxiety ratings. | This tested an acute drug effect, not treatment of an anxiety disorder, OCD or autism. It does not validate a retail strain or make THC safe for psychosis. Source |
| Myrcene | Associated with some indica labeling in a chemical/genetic study. | A relationship with a label is not proof of a sedating or anti-anxiety treatment effect in a patient. Source |
| Linalool | One of the terpenes included in NCCIH’s mechanistic pain-research priorities. | Research interest is not an established treatment indication for anxiety, OCD or autism. Source |
| Alpha-/beta-pinene | Also under study as components of cannabis and other plants. | A chemical name on a label does not establish improved focus or a predictable psychiatric effect. Source |
| Beta-caryophyllene | Investigated for potential biological effects, including pain pathways. | Mechanistic work cannot establish that a marketed blend will help a particular person. Source |
Ask for the product’s measured composition and testing information. Neither a terpene profile nor an “entourage” claim replaces clinical evidence. Do not try to reproduce laboratory terpene experiments by adding essential oils to products.
BEFORE ANY TREATMENT DECISION
Safety is part of the evidence.
Interactions & monitoring
CBD can cause liver injury, drowsiness and gastrointestinal effects, and can change how other drugs work. Combining it with alcohol or sedating medicines may increase sedation. Retail products may have inaccurate ingredient amounts or contamination. Ask a clinician or pharmacist to review the complete medication list. Source
Day-to-day risks
Cannabis may impair driving and can lead to dependence. Accidental ingestion is dangerous for children; secure storage matters. Pregnancy and breastfeeding require special caution. If new hallucinations, severe confusion or paranoia appear after use, seek prompt clinical help; call emergency services if there is immediate danger. Source
Medical cannabis in Florida
The state requires a qualified physician’s assessment of a qualifying condition, registry entry and an active identification card. The official OMMU site explains eligibility and how to check physician qualifications. A diagnosis mentioned in this article does not automatically establish eligibility or medical suitability. Source
Read Florida’s official patient information ↗HOPE ON THE HORIZON
Follow research without turning it into a promise.
More precise cannabinoid studies
Future studies need larger groups, well-defined formulations, meaningful primary outcomes and longer safety follow-up. The small 2026 autism study illustrates why encouraging secondary results still need confirmation. Source
Save a research questionTerpenes & minor cannabinoids
NCCIH has supported research into possible pain mechanisms. The limonene experiment is an early human example of studying an interaction; it is not a timeline for a new medicine. Source · Source
Learn how to assess a study →In your Care Plan, save a research question for review, record the next clinician discussion, and add a target date to revisit it. Put an actual appointment on the calendar only when it is planned. Trial status, eligibility and location must be checked with the study team; no benefit or access is guaranteed.
Bring better questions to the appointment.
Which specific symptom are we trying to improve, and how would we measure meaningful benefit?
Add for clinician reviewWhat established treatments or supports should we compare with this option?
Add for clinician reviewHow does any personal or family history of psychosis, mania, or substance-use problems change the risks?
Add for clinician reviewCould this interact with current prescriptions, over-the-counter medicines or supplements? Would blood tests or other monitoring be needed?
Add for clinician reviewWhat exact product and ingredients are being discussed? How are THC content, consistency and contaminants checked?
Add for clinician reviewWho will coordinate with the psychiatrist or other treating clinicians? When will we review benefit, side effects and functioning?
Add for clinician reviewWhat symptoms mean we should contact you urgently, and what is the agreed plan if the treatment is not helping?
Add for clinician reviewSources
Sources checked October 8, 2026. This educational article has not yet received clinical review. Research results describe particular formulations and populations, not interchangeable products.
- Cannabis research and drug approvals FDA
- Epidiolex prescribing information (2025) FDA
- CBD products: safety, interactions and unanswered questions FDA
- Cannabis and cannabinoids: what you need to know NIH / NCCIH
- Cannabis and mental health CDC
- Acute effects of cannabinoids on OCD: placebo-controlled laboratory study Kayser et al., Depression and Anxiety (2020)
- CBD and social relating, anxiety and parental stress: pilot crossover trial Parrella et al., Autism Research (2026)
- Cannabis labeling and variation in terpene synthase genes Watts et al., Nature Plants (2021)
- Research on mechanisms of terpenes and minor cannabinoids NIH / NCCIH
- Controlled study of d-limonene and THC-induced anxiety Johns Hopkins Medicine (2024)
- Medical marijuana patient requirements and physician information Florida Department of Health / OMMU